e-learning
resources
Breathe
2020
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The adoption of nintedanib in systemic sclerosis: the SENSCIS study
Teresa Bruni, Francesco Varone
Source:
Breathe, 16 (2) 200005; 10.1183/20734735.0005-2020
Journal Issue:
June
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Teresa Bruni, Francesco Varone. The adoption of nintedanib in systemic sclerosis: the SENSCIS study. Breathe, 16 (2) 200005; 10.1183/20734735.0005-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Definition and history of sarcoidosis
Related content which might interest you:
The genetics of systemic sclerosis
Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension
Year: 2008
Clinical feature of systemic sclerosis associated with pulmonary hypertension: results of one center study
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008
Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicentered open-label study
Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Year: 2008
Dose adjustments in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)
Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases
Year: 2019
Exercise limitation in systemic sclerosis
Source: Eur Respir J 2005; 26: Suppl. 49, 107s
Year: 2005
Clinical and laboratory features of systemic sclerosis with pulmonary involvement
Source: Eur Respir J 2001; 18: Suppl. 33, 512s
Year: 2001
Significance of pulmonary involvement in systemic sclerosis (SSc)– data from the German SSc-network
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Year: 2018
Etiologic factors in patients with systemic sclerosis
Source: Eur Respir J 2006; 28: Suppl. 50, 98s
Year: 2006
Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc)
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension
Year: 2019
Pulmonary involvement and exercise limitation in patients with systemic sclerosis
Source: Eur Respir J 2004; 24: Suppl. 48, 53s
Year: 2004
Experimental modeling of lung involvement due to systemic sclerosis.
Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment
Year: 2020
Rationale and design of the screening of pulmonary hypertension in systemic lupus erythematosus (SOPHIE) study
Source: ERJ Open Res, 4 (1) 00135-2017; 10.1183/23120541.00135-2017
Year: 2018
Pulmonary involvement in systemic sclerosis
Source: Eur Respir Monogr 2019; 86: 90-105
Year: 2019
Evidence-based consensus recommendations for the identification and management of interstitial lung disease in systemic sclerosis
Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Year: 2019
Pulmonary hypertension in systemic sclerosis: different phenotypes
Source: Eur Respir Rev, 26 (145) 170056; 10.1183/16000617.0056-2017
Year: 2017
Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study
Source: Eur Respir J, 53 (2) 1800081; 10.1183/13993003.00081-2018
Year: 2019
Incidence of pulmonary arterial hypertension related to systemic sclerosis: a 3-year nationwide longitudinal study
Source: Annual Congress 2008 - Pulmonary arterial hypertension and other pulmonary vascular diseases
Year: 2008
Induced sputum in systemic sclerosis: A new potential for biomarkers in SSc
Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Year: 2019
Pulmonary arterial hypertension: screening challenges in systemic sclerosis and future directions
Source: Eur Respir J, 49 (5) 1700522; 10.1183/13993003.00522-2017
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept